eli lilly glp-1 sales performance is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating Eli Lilly & Novo Nordisk
Description
This review outlines the rationale for their development and summarizes clinical trial data, focusing on retatrutide, the most advanced candidate
The best-supported ingredient in the booster category
Among Glapp users consistently engaging with their data in early treatment, weight loss outcomes exceed clinical trial benchmarks by 2545% in relative terms across both semaglutide and tirzepatide
In midlife physiology, dose decisions should reflect hormonal status, metabolic baseline, and lean mass preservation strategy
